The latest treatments for overactive bladder (non-neurological) syndrome in women and men.

The latest treatments for overactive bladder (non-neurological) syndrome in women and men.

The urgency and stress incontinence are considered as one of the chronic diseases affects more than more than 15 million people in U.S.A and is a major problem in aging adults male and female.

Overactive bladder syndrome, called urge incontinence, may be diagnosed when symptoms of both daytime and nighttime urinary frequency and urgency. 

Urge Urinary syndrome affects elderly patients who suffer highly from metabolic diseases such as diabetes, obesity as well as from acute and chronic urinary tract infections. The Diagnosis should be managed through urinalysis and urine culture, examination of the bladder and uroflow strength by urodynamic.

The symptoms are the complaint of a sudden compelling desire to pass urine which is difficult to defer, and involuntary leakage of urine associated with sudden compelling desire to void.

Recent clinical studies have indicated that the increased activity of the bladder muscle is due to pathological factors, such as acute, recurrent and chronic inflammatory disease in a premenopausal, menopausal, and postmenopausal woman and as well in men less than 40 years old, suffers from acute, recurrent or chronic prostatitis, and as well suffers from obstructive prostatic enlargement, or is following Neuro-Urological Disorders due to suprapontine and pontine lesions and diseases or lesions and diseases between caudal brainstem and sacral spinal cord, as well as due to changes in the sensitivity of the bladder wall towards the stimuli present in the urine. In recent years, high-efficacy drug therapy for overactive bladder, urge incontinence has witnessed great developments. 

The European Society of Urology has strongly recommended to reduce of the detrusor overactivity, as the use of beta-3 adrenoreceptor (β3-AR) agonists (mirabegron), or antimuscarinics (solifenacin), alpha-blockers, and botulinum toxin A (Botox A) as intra vesical treatment. These all to suppress the neurotransmitter present in the membrane and bladder muscle.

Prof. Dr. Semir Al-Samarrai

Post a comment

Your email address will not be published. Required fields are marked *

Book an appointment now

MOH Application Number: BD76722
Expiry Date: 15-10-2021